US patent issued for BCM-95 Curcumin

Allows the turmeric extract to be used as a potential treatment for Alzheimer's disease

BCM-95 Curcumin, the patented turmeric extract formulation from Indian company Arjuna Natural Extracts, has received a US patent for its use as a potential treatment for Alzheimer's disease. The patent describes the unique combination of beneficial curcuminoids and turmeric essential oil in BCM-95, as well as its enhanced absorption and bioavailability.

The product has already undergone human clinical trials in patients with Alzheimer's disease at Chinese University of Hong Kong under Professor Larry Baum (2008). It was found to be highly beneficial in preventing further cognitive decline, reducing amyloid beta plaques, one of the major causes of Alzheimer's disease, increasing vitamin E levels in the body, and enhancing curcumin levels in blood.

Under Professor Ralph Martins in Australia, BCM-95 Curcumin is also undergoing two other human clinical trials in patients with Alzheimer's disease and in subjects at risk of developing the disease.

'These research findings will open a new world of hope to the millions battling Alzheimer's every day, as they will now have a natural and safe alternative for addressing Alzheimer's,' said Benny Antony, Joint Managing Director of Arjuna Natural Extracts, based in Kerala, and the inventor of BCM-95.

BCM-95 Curcumin has 12 granted and 15 ongoing patents in India, US and Japan and more patents pending worldwide. It is also being studied for various indications including inflammation, arthritis, diabetes, depression, cancer prevention and treatment, as an adjuvant to chemotherapy and cancer radiation, and in liver and gastrointestinal diseases.

Companies